Cardiology, Drug Trials, FDA Approval and Trials

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Cardiology

Drug Trials

FDA Approval

Trials

Vicore initiates clinical proof-of-concept study of endothelial dysfunction

Drug Discovery World

MAY 3, 2023

Vicore Pharma, a Swedish clinical-stage pharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists (ATRAGs), has dosed its first patient with C21 in a clinical study of endothelial dysfunction. Vicore Pharma states that results from the trial are expected in Q4, 2023.

Cardiology

Cardiology Trials FDA Approval Drug Trials

Cardiovascular Clinical Trials with Patient Diversity: Challenges and Considerations

XTalks

AUGUST 4, 2022

Cardiovascular clinical trials need to have a diversity plan because there can be a difference in disease burden when comparing people of different race and ethnicity. The US Food and Drug Administration (FDA) is emphasizing the need for diversity in clinical trials. The Diversity of the US Population.

Clinical Trials

Clinical Trials Clinical Trials Trials Clinical Research

Clinical Research Informer

Vicore initiates clinical proof-of-concept study of endothelial dysfunction

Cardiovascular Clinical Trials with Patient Diversity: Challenges and Considerations

Stay Connected